Sodium and potassium channel modulators: their role in neuroprotection.
Obrenovitch
T P
TP
Department of Neurochemistry, Institute of Neurology, London, UK.
D000818:Animals; D044482:Benzeneacetamides; D002470:Cell Survival / Q000187:drug effects; D004195:Disease Models, Animal; D000077213:Lamotrigine; D009474:Neurons / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D015221:Potassium Channels / Q000187:drug effects*; D011743:Pyrimidines / Q000494:pharmacology; D019782:Riluzole; D015222:Sodium Channels / Q000187:drug effects*; D013844:Thiazoles / Q000494:pharmacology; D014227:Triazines / Q000494:pharmacology
D044482:Benzeneacetamides; D018696:Neuroprotective Agents; D010879:Piperazines; D010880:Piperidines; D015221:Potassium Channels; D011743:Pyrimidines; D015222:Sodium Channels; D013844:Thiazoles; D014227:Triazines; C078265:5-(2,3,5-trichlorophenyl)pyrimidine-2,4-diamine ethane sulfonate; C081801:PD 85639; D019782:Riluzole; C081980:sipatrigine; D000077213:Lamotrigine